Fluvoxamine as a cause of stimulation, mania and aggression with a critical analysis of the FDA-approved label

International Journal of Risk and Safety in Medicine

Volumn 14, Issue 3-4, 2001, Pages 71-86

  Breggin, Peter R ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AGGRESSION; ARTICLE; BRAIN DEPTH STIMULATION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFECT; FOOD AND DRUG ADMINISTRATION; HUMAN; MANIA; OBSESSION; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOLOGY;

EID: 0035552005     PISSN: 09246479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Serotonin syndrome and fluvoxamine: A case study
2. The abrupt discontinuation of fluvoxamine in patients with panic disorder
3. Antidepressant drugs
4. Mania and fluvoxamine
5. Paroxetine-induced mania
6. Fluvoxamine (Faverin): Adverse reaction profile
7. Effects of serotonin reuptake inhibitors on aggressive behavior in psychiatrically hospitalized adolescents: Results of an open trial
8. Serotonin reuptake inhibitor withdrawal
9. Fluvoxamine-associated manic behavior: A case series
10. The serotonin syndrome and psychosis-like side effects of fluvoxamine in clinical use - An estimation of incidence
11. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression
12. Violent acts associated with fluvoxamine treatment
13. Emergency of antidepressant induced suicidality
14. Paroxetine, sertraline, and fluvoxamine: New selective serotonin reuptake inhibitors
15. Apathy and indifference in patients on fluvoxamine and fluoxetine
16. Induction of mania with serotonin reuptake inhibitors
17. Fluvoxamine (DU-23,000), a new antidepressant. Quantitative pharmaco-electroencephalography and pilot clinical trials
18. Fluoxetine in children and adolescents with mood disorders: A chart review of efficacy and adverse reactions
19. Introducing MEDWatch: A new approach to reporting medication and device adverse effects and product problems
20. Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment
21. Premarketing safety evaluation of new drugs
22. Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance
23. Top drugs firm admits bribes
24. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies
25. Psychopharmacology and electroconvulsive therapy
26. Fluvoxamine approved for childhood OCD
27. Principles of therapeutics
28. Violent acts associated with fluvoxamine treatment
29. Paroxetine-induced mania
30. Fluvoxamine: Study of treatment effect on a group of 189 hospitalized patients with depression
31. Behavioral side of fluoxetine in children and adolescents
32. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial
33. Reexposure to fluoxetine after serious suicide attempts by three patients: The role of akathisia
34. Psychopharmacology and electroconvulsive therapy
35. A single dose of fluvoxamine associated with an acute psychotic reaction
36. Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability
37. Antidepressant drugs and the emergence of suicidal tendencies
38. Partial generalization of (-) DOM to fluvoxamine in the rat: Implications for SSRI-induced mania and psychosis
39. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: A literature review